Table 4 Characteristics of Phase 2 patients who had objective responses after treatment with IL-21 plus sorafenib
From: Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
Subject | Best response (Independent assessment) | Site(s) of disease | Prior therapy(ies) |
|---|---|---|---|
1021 | PR | Liver, LNs | Sunitinib, Temsirolimus |
1027 | PR | Lung, LNs, pancreas, bone | Pazopanib |
2036 | PR | Kidney, adrenal, lungs | Temsirolimus |
2041 | PR | Liver, tongue | Cediranib |
2042 | PR | Liver, lung | Sunitinib |
2045 | PR | LNs, liver | High-dose IL-2 |
2046 | PR | Pancreas, lung, LNs, bone, peritoneum | Temsirolimus |